{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:17:16Z","timestamp":1782317836042,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T00:00:00Z","timestamp":1406592000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/2008-2231-22-58","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T13:01:46Z","timestamp":1406638906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with 90Y and 111In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Nazila","family":"Gholipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Jalilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Khalaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Johari-Daha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Yavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Sabzevari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Reza","family":"Khanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Akhlaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,29]]},"reference":[{"key":"220_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-006-0087-6","volume":"6","author":"RO Dillman","year":"2006","unstructured":"Dillman RO: Radioimmunotherapy of B-cell lymphoma with radiolabeled anti-CD20 monoclonal antibodies. Clin Exp Med. 2006, 6: 1-12. 10.1007\/s10238-006-0087-6.","journal-title":"Clin Exp Med"},{"key":"220_CR2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998, 16: 2825-2833.","journal-title":"J Clin Oncol"},{"key":"220_CR3","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","volume":"95","author":"JD Hainsworth","year":"2000","unstructured":"Hainsworth JD, Burris HA, Morrissey LH, Litchy S, Scullin DC, Bearden JD, Richards P, Greco FA: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000, 95: 3052-3056.","journal-title":"Blood"},{"key":"220_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ijrobp.2006.05.030","volume":"66","author":"RM Macklis","year":"2006","unstructured":"Macklis RM, Pohlman B: Radioimmunotherapy for non-Hodgkin\u2019s lymphoma: a review for radiation oncologists. Int J Radiat Oncol Biol Phys. 2006, 66: 833-841. 10.1016\/j.ijrobp.2006.05.030.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"220_CR5","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1200\/JCO.2005.05.3470","volume":"24","author":"MF Leahy","year":"2006","unstructured":"Leahy MF, Seymour JF, Hicks RJ, Turner JH: Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2006, 24: 4418-4425. 10.1200\/JCO.2005.05.3470.","journal-title":"J Clin Oncol"},{"key":"220_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1269\/jrr.46.241","volume":"46","author":"I Skvortsova","year":"2005","unstructured":"Skvortsova I, Popper BA, Skvortsov S, Saurer M, Auer T, Moser R, Kamleitner H, Zwierzina H, Lukas P: Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin\u2019s lymphoma cells. J Radiat Res. 2005, 46: 241-248. 10.1269\/jrr.46.241.","journal-title":"J Radiat Res"},{"key":"220_CR7","first-page":"215","volume":"1","author":"SA Jacobs","year":"2007","unstructured":"Jacobs SA: Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin\u2019s lymphoma: current status and future prospects. Biologics. 2007, 1: 215-227.","journal-title":"Biologics"},{"key":"220_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00259-007-0372-y","volume":"34","author":"J Tennvall","year":"2007","unstructured":"Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, Lassmann M, Oyen W, Brans B, Therapy Committee, EANM; Oncology Committee, EANM; Dosimetry Committee, EANM: EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabeled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007, 34: 616-622. 10.1007\/s00259-007-0372-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"220_CR9","first-page":"391","volume":"84","author":"MR Chamarthy","year":"2011","unstructured":"Chamarthy MR, Williams SC, Moadel RM: Radioimmunotherapy of non-Hodgkin\u2019s lymphoma: from the \u2018magic bullets\u2019 to \u2018radioactive magic bullets\u2019. Yale J Biol Med. 2011, 84: 391-407.","journal-title":"Yale J Biol Med"},{"key":"220_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1053\/j.semnuclmed.2005.02.006","volume":"35","author":"GL DeNardo","year":"2005","unstructured":"DeNardo GL: Treatment of Non-Hodgkin\u2019s Lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med. 2005, 35: 202-211. 10.1053\/j.semnuclmed.2005.02.006.","journal-title":"Semin Nucl Med"},{"key":"220_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00259-005-1798-8","volume":"32","author":"C Antonescu","year":"2005","unstructured":"Antonescu C, Bischof Delaloye A, Kosinski M, Monnin P, Schaffland AO, Ketterer N, Grannavel C, Kovacsovics T, Verdun FR, Buchegger F: Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics. Eur J Nucl Med Mol Imaging. 2005, 32: 943-951. 10.1007\/s00259-005-1798-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"220_CR12","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1200\/JCO.2005.01.0892","volume":"23","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL: Re-treatment with I-131 tositumomab in patients with non-Hodgkin\u2019s lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005, 23: 7985-7993. 10.1200\/JCO.2005.01.0892.","journal-title":"J Clin Oncol"},{"key":"220_CR13","first-page":"394","volume":"4","author":"M Vaes","year":"2012","unstructured":"Vaes M, Bron D, Vugts DJ, Paesmans M, Meuleman N, Ghanem GE, Guiot T, Vanderlinden B, Thielemans K, Van Dongen G, Flamen P, Muylle K: Safety and efficacy of radioimmunotherapy with 90Yttrium-rituximab in patients with relapsed CD20+ B cell lymphoma: a feasibility study. J Cancer Sci Ther. 2012, 4: 394-400.","journal-title":"J Cancer Sci Ther"},{"key":"220_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/0973-1482.113350","volume":"9","author":"N Gholipour","year":"2013","unstructured":"Gholipour N, Vakili A, Radfar E, Jalilian AR, Bahrami-Samani A, Shirvani-Arani S, Ghannadi-Maragheh M: Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy. J Can Res Ther. 2013, 9: 199-204. 10.4103\/0973-1482.113350.","journal-title":"J Can Res Ther"},{"key":"220_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3797\/scipharm.0804-07","volume":"76","author":"AR Jalilian","year":"2008","unstructured":"Jalilian AR, Sardari D, Kia L, Rowshanfarzad P, Garousi J, Akhlaghi M, Shanehsazzadeh S, Mirzaii M: Preparation, quality control and biodistribution studies of two [111In]-Rituximab immunoconjugates. Sci Pharm. 2008, 76: 151-170. 10.3797\/scipharm.0804-07.","journal-title":"Sci Pharm"},{"key":"220_CR16","first-page":"271","volume":"54","author":"A Bahrami-Samani","year":"2009","unstructured":"Bahrami-Samani A, Ghannadi-Maragheh M, Jalilian AR, Yousefnia H, Garousi J, Moradkhani S: Development of 153Sm-DTPA-rituximab for radioimmunotherapy. Nukleonika. 2009, 54: 271-277.","journal-title":"Nukleonika"},{"key":"220_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.apradiso.2011.01.026","volume":"69","author":"PF Audicio","year":"2011","unstructured":"Audicio PF, Castellano G, Tassano MR, Rezzano ME, Fernandez M, Riva E, Robles A, Cabral P, Balter H, Oliver P: [177Lu]DOTA-anti-CD20: labeling and pre-clinical studies. Appl Radiat Isot. 2011, 69: 924-928. 10.1016\/j.apradiso.2011.01.026.","journal-title":"Appl Radiat Isot"},{"key":"220_CR18","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00259-009-1120-2","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Chen J, Fani M, Powell P, Lohri A, M\u00fcller-Brand J, Moldenhauer G, Maecke HR: In vitro characterization of (177)Lu-radiolabeled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging. 2009, 36: 1443-1452. 10.1007\/s00259-009-1120-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"220_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10967-010-0676-4","volume":"287","author":"H Yousefnia","year":"2011","unstructured":"Yousefnia H, Radfar E, Jalilian AR, Bahrami-Samani A, Shirvani-Arani S, Arbabi A, Ghannadi-Maragheh M: Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy. J Radioanal Nucl Chem. 2011, 287: 199-209. 10.1007\/s10967-010-0676-4.","journal-title":"J Radioanal Nucl Chem"},{"key":"220_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10967-006-6961-6","volume":"274","author":"AR Jalilian","year":"2007","unstructured":"Jalilian AR, Mirsadeghi L, Yari-kamrani Y, Rowshanfarzad P, Kamali-dehghan M, Sabet M: Development of [64Cu]-DOTA-anti-CD20 for targeted therapy. J Radioanal Nucl Chem. 2007, 274: 563-568. 10.1007\/s10967-006-6961-6.","journal-title":"J Radioanal Nucl Chem"},{"key":"220_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1021\/bc700328s","volume":"19","author":"LM De Le\u00f3n-Rodr\u00edguez","year":"2008","unstructured":"De Le\u00f3n-Rodr\u00edguez LM, Kovacs Z: The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem. 2008, 19: 391-402. 10.1021\/bc700328s.","journal-title":"Bioconjug Chem"},{"key":"220_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0969-8051(03)00033-7","volume":"30","author":"LL Chappell","year":"2003","unstructured":"Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP: Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N, N\u2019, N\u201d, N\u201d\u2019-tetraacetic acid for radiolabeling proteins. Nucl Med Biol. 2003, 30: 581-595. 10.1016\/S0969-8051(03)00033-7.","journal-title":"Nucl Med Biol"},{"key":"220_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10967-007-7212-1","volume":"278","author":"H Sadeghpour","year":"2008","unstructured":"Sadeghpour H, Jalilian AR, Akhlaghi M, Kamali-dehghan M, Mirzaii M: Preparation and biodistribution of [111In]- rHu Epo for erythropoietin receptor imaging. J Radioanal Nucl Chem. 2008, 278: 117-122. 10.1007\/s10967-007-7212-1.","journal-title":"J Radioanal Nucl Chem"},{"key":"220_CR24","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10967-013-2426-x","volume":"296","author":"A Vakili","year":"2013","unstructured":"Vakili A, Jalilian AR, Yavari K, Shirvani-Arani S, Khanchi AR, Bahrami-Samani A, Salimi B, Khorrami-Moghadam AR: Preparation and quality control and biodistribution studies of [90Y]-DOTA-cetuximab for radioimmunotherapy. J Radioanal Nucl Chem. 2013, 296: 1287-1294. 10.1007\/s10967-013-2426-x.","journal-title":"J Radioanal Nucl Chem"},{"key":"220_CR25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0969-8051(99)00054-2","volume":"26","author":"E Dadachova","year":"1999","unstructured":"Dadachova E, Chappell LL, Brechbiel MW: Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol. 1999, 26: 977-982. 10.1016\/S0969-8051(99)00054-2.","journal-title":"Nucl Med Biol"},{"key":"220_CR26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/227680a0","volume":"227","author":"UK Laemmli","year":"1970","unstructured":"Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038\/227680a0.","journal-title":"Nature"},{"key":"220_CR27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/10826076.2012.673210","volume":"36","author":"AR Jalilian","year":"2013","unstructured":"Jalilian AR, Akhlaghi M: HPLC analysis of radiogallium labeled proteins using a two solvent system. J Liq Chromatogr Related Technol. 2013, 36: 731-739.","journal-title":"J Liq Chromatogr Related Technol"},{"key":"220_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","volume":"72","author":"T Lindmo","year":"1984","unstructured":"Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984, 72: 77-89. 10.1016\/0022-1759(84)90435-6.","journal-title":"J Immunol Methods"},{"key":"220_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1006\/cimm.2000.1693","volume":"204","author":"D Flieger","year":"2000","unstructured":"Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I: Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000, 204: 55-63. 10.1006\/cimm.2000.1693.","journal-title":"Cell Immunol"},{"key":"220_CR30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00259-006-0160-0","volume":"33","author":"LR Perk","year":"2006","unstructured":"Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, Zijlstra JM, Huijgens PC, van Dongen GA: Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006, 33: 1337-1345. 10.1007\/s00259-006-0160-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"220_CR31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.addr.2008.04.006","volume":"60","author":"S Liu","year":"2008","unstructured":"Liu S: Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Delivery Rev. 2008, 60: 1347-1370. 10.1016\/j.addr.2008.04.006.","journal-title":"Adv Drug Delivery Rev"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2008-2231-22-58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2008-2231-22-58\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2008-2231-22-58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T18:04:24Z","timestamp":1598119464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1186\/2008-2231-22-58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,29]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1186\/2008-2231-22-58","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,29]]},"assertion":[{"value":"22 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"58"}}